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Use of MARS in Hepatorenal Syndrome —
A Local Perspective
Alexander Chiu, Sheung Tat Fan1
Hepatorenal syndrome is a complication of liver failure with high mortality. All existing treatments, short of
liver transplantation, can only be considered as supportive. The molecular adsorbent recirculation system (MARS)
is a modified dialysis technique that can remove bilirubin and other albumin-bound toxins, and is now widely
used as an artificial liver support system. MARS has been evaluated in many studies, although most have been
observational rather than randomized controlled trials. MARS has been demonstrated to be effective in attenuating
serum bilirubin, ammonia, creatinine and other hepatotoxin levels in patients, but the biochemical improvement
has not been accompanied by an improvement in patient survival. Factors that affect the outcome of patients
include timing of implementation, nature of the liver diseases treated, and availability of liver transplantation.
MARS preconditioning is another possible indication that aims to improve the postoperative outcome in elective
live donor liver transplantation. In the future, randomized controlled trials will be necessary to ascertain the
specific role of MARS in the management of liver failure. [Hong Kong J Nephrol 2006;8(1):5–9]
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INTRODUCTION
Hepatorenal syndrome (HRS) poses a unique challenge
to liver failure patients and the clinicians managing
them. HRS has a high mortality, with a median survival
of only 2 weeks as reported by Gines et al [1]. Once
HRS has developed, the sand in the hourglass starts
to dribble and patients only have a limited time if liver
transplantation or spontaneous recovery cannot be
achieved. Unlike other causes of renal failure, HRS is
unique in the sense that the pathology does not involve
the kidneys [2]; indeed, the kidneys from HRS patients
can be transplanted to others and function normally [3].
While a detailed description of the pathophysiology and
diagnosis of HRS is beyond the scope of this article,
the essential pathophysiologic feature of HRS lies in
the marked reduction in renal blood flow that is caused
by the intense vasoconstriction of the renal circulation
counteracting the pathologic vasodilatation of the
splanchnic circulation. The diagnosis of HRS requires
the demonstration of a low glomerular filtration rate and
exclusion of other causes of renal failure that might be
coexisting or superimposed on liver failure patients. The
current definition of HRS is according to a consensus
reached by the International Ascites Club in 1996 (Table)
[4]. HRS is subdivided into type 1 and type 2. Type 1
HRS refers to renal dysfunction that is severe and
progressive, in contrast to type 2, which is moderate
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and steadily deteriorating. Unless otherwise stated, the
discussion in this article pertains to type 1 HRS.
AVAILABLE TREATMENT FOR HRS
There are only a few treatment options available for
HRS to date. Treatments such as vasopressin ana-
logue and systemic vasoconstrictor, despite being able
to improve renal function, have not shown any survival
benefits [5–7]. The use of transjugular intrahepatic
portosystemic shunt is associated with survival bene-
fit, but is, in itself, a treatment not without risk and
which requires special expertise [8]. The efficacy of
hemodialysis and hemofiltration in HRS is uncertain,
and they are best regarded as supportive therapy only
[9].
THE MARS CIRCUIT
The molecular adsorbent recirculation system (MARS)
is a modified dialysis using albumin-enriched dialysate
to eliminate protein-bound and hydrophobic toxins in
the blood that are otherwise not removable by con-
ventional dialytic methods [10]. A patient’s blood is
dialyzed across a hybrid membrane impregnated with
albumin. These impregnated albumins serve to offer
free binding sites that help to transfer bilirubin and other
albumin-bound toxins across the synthetic membrane,
mimicking the biological transport process through the
hepatocyte [11]. Desorption of toxins is achieved by
albumin-enriched dialysate circulating in a closed loop
over the other side of the membrane. The dialysate is
regenerated online through perfusion of an activated
charcoal and cholestyramine column. A third circuit,
Major criteria
1. Chronic or acute hepatic disease and liver failure with portal hypertension
2. Serum creatinine level > 1.5 mg/dL (133 M/L) or 24-hour creatinine
clearance < 40 mL/min (0.67 mL/s)
3. Absence of shock, ongoing bacterial infection, recent use of nephrotoxic
drugs, excessive fluid or blood loss
4. No sustained improvement in renal function after volume expansion with
1.5 L isotonic saline solution
5. No clinical evidence of proteinuria, obstructive uropathy or renal
parenchymal disease
Table. Definition of hepatorenal syndrome type 1 [4]
Minor criteria
1. Urine volume < 500 mL/day
2. Urine sodium < 10 mmol/L
3. Urine osmolality > plasma osmolality
4. Urine red blood cell count < 50 per
high-power field
5. Serum sodium < 130 mmol/L
Figure. The MARS circuit. (Adapted from Gambro Renal Products Inc, with permission.)
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which could either be a hemodialysis or a hemofiltration
system, is also incorporated to remove hydrosoluble
toxins and regulate blood urea and nitrogen, fluid and
electrolytes (Figure). Hepatotoxins that have been
documented to be removable by MARS include
tryptophan, mercaptans, copper, manganese, GABA-
like substance, bile acids, aromatic acids, and short and
middle chain fatty acids [12–14]. The clinical efficacy
of MARS has been described in many reports, although
most have been observational and uncontrolled studies
[15–22]. MARS is currently one of the most commonly
used artificial liver assist devices for patients with
hepatic failure in the intensive care setting.
MARS AND SURVIVAL
There have only been a few randomized controlled trials
on MARS in liver failure, with only one that specifically
looked at HRS. Mitzner et al performed a randomized
controlled trial to assess the impact of MARS on HRS
in 13 patients [15]. Eight patients received MARS plus
standard medical therapy, and five received hemodia-
filtration and standard medical therapy as the control.
The results showed a marked prolongation of survival
in the MARS group of 25.2  34.7 days compared with
4.6  1.8 days in the control group (p < 0.05). There
was, however, no difference in mortality by 3 months.
There were a few points worth noting in this study. In
the recruitment of patients, the authors had selected
those who did not only fulfill the International Ascites
Club definition but also the criteria proposed by Epstein
[23]. The creatinine level that defines HRS was the
same in both criteria but, in the latter, it also required
the patient to have oliguria < 500 mL/day and urine
sodium < 20 mmol/L. The condition of the study
patients was, therefore, more advanced and excep-
tionally ill. In an uncontrolled study (by the same
research group) in which the International Ascites
Club criteria were the only diagnostic criteria adopted
for HRS, the survival rate of the MARS group was
significantly higher than that of the control group [24].
It is possible that, in advanced liver failure, multiorgan
involvement has already occurred and overwhelmed
any benefit that might have been gained by MARS.
Mitzner et al’s study [15] clearly demonstrated pro-
longation of survival with MARS treatment. Pro-
longing survival for a short period of time may not be
meaningful in itself, but if survival prolongation can be
linked to an increased chance of obtaining liver trans-
plantation, the potential benefit of MARS as a bridg-
ing treatment is much amplified. The poor overall
survival in the study [15] may be explained by the fact
that a significant proportion of patients (7 of 13) had
alcoholic liver disease not abstinent at the time of
enrolment, implying that they were not eligible for liver
transplantation. The role of MARS as a bridging treat-
ment could, therefore, be undervalued.
MARS VS. HEMODIAFILTRATION
In the study by Mitzner et al [15], MARS was compared
against a control group treated with hemodiafiltration,
suggesting that any difference seen was not due to the
dialytic component of MARS alone. Such differences
may be attributable to some putative toxins that were
removed by MARS but not by conventional dialysis.
Nitric oxide (NO2) released by vascular endothelial cells
is a mediator that is well recognized to be a potent
vasodilator, with a major role in the regulation of
vascular resistance [25]. NO2 synthesis is increased in
cirrhosis, and there is evidence suggesting that it is
linked to the pathogenesis of HRS [26]. NO2 in the form
of nitrite is highly water-soluble and removable through
hemofiltration. Nitrate, the major component of NO2,
on the contrary, is highly albumin-bound and removable
only through the anion exchange column of the MARS
system. The removal of NO2 may alter the vasoresis-
tance of the splanchnic arterial bed and, hence, reverse
HRS. The removal of NO2 has other benefits like
increasing systemic vascular resistance, and there is also
emerging evidence that suggests that NO2 is associated
with the development of hyperammonemia and hepatic
encephalopathy [27]. Another point of interest is that
NO2 levels have been observed to remain low even after
7 days following a single MARS treatment [14]. It has
been postulated that MARS dialysis might interfere with
NO2 production through the removal of tumor necrosis
factor- [28], which is a potent mediator of inflammation
that modulates damage in liver injury.
LOCAL EXPERIENCE WITH MARS
By the end of 2005, more than 130 MARS sessions
had been performed in 40 patients in Queen Mary
Hospital, Hong Kong. The results have been reported
elsewhere [29]. MARS is a safe procedure, and there
have been no mortalities directly related to the use of
it. Significant reductions in serum bilirubin, ammonia
and creatinine levels were the most consistent effects
observed, but in most cases, the biochemical improve-
ment could not be translated into survival benefit.
We have had three patients who were able to bridge to
liver transplantation, and one of them spontaneously
recovered, although it would be difficult to credit it to
MARS alone. We have not been able to observe any
spontaneous reversal of HRS in patients who underwent
MARS treatment. Such initial results did not appear to
be promising, and the efficacy of MARS has been
seriously questioned as MARS dialysis is an expensive
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procedure, costing about US$3,850 per session. It
should be noted, however, that liver failure is a disease
with a poor prognosis, and the expectation that MARS
would lead to a dramatic improvement in the outcome
of liver failure is not realistic, as the liver is a complex
organ, and management of liver failure constitutes a
great deal more than detoxification alone. One of the
main reasons that might account for our results was
that the initiation of MARS was not early enough
in many patients. The impact of this factor is most
significant in the context of HRS, where the mortality
is high and the duration of survival is short. Performing
MARS only when the diagnosis is absolutely certain
may not be in the best interests of the patient. A more
proactive approach would be to commence treatment
when there is a rising creatinine level leading to the
suspicion of HRS, while at the same time performing a
fast-track diagnostic rundown to exclude other causes
of renal failure. Our unit is currently designing a trial
to assess if early intervention with MARS would lead
to a difference in outcome in patients with liver failure.
Another factor affecting the outcome of MARS
treatment is the nature of the liver disease treated.
Patients treated with MARS in our unit included those
who suffered from acute liver failure, acute-on-chronic
liver failure, post-hepatectomy liver failure or post-
transplantation liver failure. The number of patients
treated in each subgroup was too small for us to be
able to comment on what type of patient would benefit
from MARS. Overall, judging from the literature and
our experience, patients with acute liver failure who
are treated with MARS would appear to have the highest
probability of bridging to spontaneous recovery. The
outcome of patients with acute-on-chronic liver failure
is more variable, being strongly dependent on whether
liver transplantation can be achieved. The use of MARS
in graft dysfunction is mostly considered a salvage
therapy and, in some cases, could obviate the need for
retransplantation. The use of MARS in post-hepatec-
tomy liver failure is associated with the worst outcome
as most cases failed to survive until liver regeneration.
In Hong Kong, where the number of liver grafts
available is low, the majority of patients who were
put on MARS while awaiting cadaveric grafts even-
tually succumbed without access to orthotopic liver
transplantation. The dilemma that arises from such an
organ shortage is how one can determine when MARS
should be terminated if the chance of obtaining a liver
transplantation is so dismal. Our current policy supports
all potential transplant recipients in the optimism that
they will be able to bridge to liver transplantation. The
support shall cease, however, when the other physical
parameters of the patient deteriorate to a state that
renders the patient not suitable for transplantation.
Patients with HRS who have undergone trans-
plantation and those with preoperative renal failure have
a tendency not to do well in their postoperative period
[30–33]. Choi et al compared patients who received
MARS as a preconditioning treatment just before liver
transplantation with historic controls, and reported that
the preconditioned, treatment, group had a higher
survival rate than the control group [34]. A single
MARS session, excluding the time required for priming
the device, takes around 6–8 hours, so the treatment
is not quite practical if performed before emergency
cadaveric liver transplantation. In Hong Kong, where
live donor liver transplantation is commonly practiced,
MARS preconditioning could be easily carried out
while the live donor is being investigated and prepared
for surgery. In our center, we are investigating the pos-
sibility of using MARS preconditioning in patients
who are planning for living-related liver transplantation
and who have already been suffering from complications
of liver failure such as HRS. The theoretical benefits
of MARS preconditioning include regulating fluid
balance, improving systemic vascular resistance, and
reducing the incidence of postoperative renal failure.
Given the current evidence, we do not consider
MARS to be a cost-effective treatment that should be
recommended for routine use in all liver failure pa-
tients. MARS dialysis is certainly an area worth further
exploration, preferably in the format of randomized
controlled trials. Patient outcome is strongly depen-
dent on the timing of implementation, the nature of
the liver disease treated, and the availability of liver
transplantation. Future research should be directed
accordingly to identify the appropriate indications,
timing of intervention, and the other technical aspects
of treatment. Liver transplantation is, by far, the only
effective treatment for liver failure, but we believe
MARS to have the potential to be developed into a
valuable complementary measure in the management
of patients with liver failure.
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